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routine service cost, and cost of adverse event treatment. RESULTS: EGFR-TKI treat-
ment provided a better progression-free survival and overall survival compared with 
docetaxel. Except rash, dry skin and dry eyes, the incidence of other adverse events 
in patients treated with EGFR-TKI was lower than docetaxel. However, the monthly 
treatment cost and total treatment costs of EGFR-TKI were higher than docetaxel at 
37,017.55 baht/month and 451,071.08 baht respectively. The incremental cost-effec-
tiveness ratio (ICER) was 631,426.01 baht/life-year-gained (LYG). CONCLUSIONS: 
Though EGFR-TKI has a more favorable clinical outcome than docetaxel, the addi-
tional cost per LYG is signiﬁ cant. This ICER is greater than the threshold suggested 
by the WHO, three times of GDP/capita (300,000 baht), which may consider to be 
not cost-effective. Both docetaxel and EGFR-TKI are the effective and available treat-
ments for aNSCLC in Thailand. When making a decision and policy regarding the 
treatments of aNSCLC, this economic evidence should be taken into account along 
with other clinical aspects. 
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OBJECTIVES: Cetuximab, a monoclonal antibody directed against the epidermal 
growth factor receptor, improves progression free survival and overall survival for 
metastatic colorectal cancer (mCRC) patients. However patients with K-ras mutation 
don’t beneﬁ t from cetuximab. METHODS: We performed cost-effectiveness analysis 
of K-ras testing and cetuximab treatment as last-line therapy for mCRC patients. In 
our analysis, we considered three groups: A) cetuximab treatment for patients with 
wild-type tumors and best supportive care (BSC) for mutant patients with K-ras 
testing; B) cetuximab treatment for all the patients without K-ras testing; and C) BSC 
for all the patients without K-ras testing. The cost-effectiveness of three comparison 
groups was calculated: group A versus B (cost-effectiveness of K-ras testing), group A 
versus C (cost-effectiveness of cetuximab treatment with K-ras testing), and group B 
versus C (cost-effectiveness of cetuximab treatment without K-ras testing). Con-
structed three-state Markov model was used to predict expected costs and outcome 
of each group. Outcome was based on the report by Karapetis et al. (2008), who 
retrospectively analyzed NCIC CTG CO. 17. Only direct medical costs were included 
from the perspective of Japanese health-care payer. Three percent discount rate was 
used for both costs and outcome. RESULTS: K-ras testing for cetuximab treatment 
reduced costs by JPY 500,000 per patients. Budget impact was estimated to be JPY 3 
to 5 billion. However, the ICER of cetuximab with K-ras testing was more than JPY 
10 million per life-year gained (LYG) although it was smaller than ICER of cetuximab 
without K-ras testing. Even if the mean utility score was 0.7, the ICER was approach-
ing JPY 20 million per QALY. CONCLUSIONS: When the cetuximab treatment is 
administered as last-line therapy for mCRC patients, K-ras testing is recommended. 
However, the ICER of cetuximab treatment is too high, even if the treatment is limited 
to patients with wild-type K-ras. 
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OBJECTIVES: To elucidate the more cost-effective dosing strategy for the administra-
tion of pemetrexed in the second-line treatment of patients having been treated for 
advanced non-small cell lung cancer (NSCLC). METHODS: Validation of the model 
was based on efﬁ cacy and safety data from a phase II clinical study conducted in Japan 
of two pemetrexed doses: 500 mg/m2 (P500) versus 1000 mg/m2 (P1000). Cost-effec-
tiveness and cost-minimization analyses were performed to estimate the impact of 
P500 versus P1000 on expected life-years and costs from the perspective of the Japa-
nese national health insurance (NHI) system. Costs covered additional treatment and 
test which are needed due to the treatment of pemetrexed and adverse events. A sub-
group analysis was conducted to compare the cost-effectiveness of pemetrexed in 
patients with different NSCLC histologies. RESULTS: P1000 exhibited a negative 
life-years gained (LYG) of −0.115 at an incremental cost of US$13,674 compared to 
P500, implying simple dominance of P500 over P1000. The incremental cost-effec-
tiveness ratio (ICER) of pemetrexed therapy with P500 was estimated at US$19,479/
LYG, compared with the same therapy in squamous cell carcinoma, when it is per-
formed in non-squamous cell carcinoma. Results of a probabilistic sensitivity analysis 
demonstrated an almost 100% likelihood of the ICER of pemetrexed with P500 for 
non-squamous cell patients falling below the threshold of US$50,000/LYG. CON-
CLUSIONS: P500 is a more cost-effective dosing regimen than P1000 for pemetrexed 
chemotherapy in patients with NSCLC. Also, results suggest that pemetrexed is more 
cost-effective in NSCLC patients of non-squamous histology than of squamous histol-
ogy from the payer’s perspective. 
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OBJECTIVES: To determine the economic implications of agents used to treat meta-
static renal cell carcinoma (mRCC). METHODS: A lifetime Markov model was 
developed to simulate the patterns of disease progression and to determine the out-
comes under treatment of available medicines including interferon-alpha (IFNa), suni-
tinib, sorafenib, and bevacizumab. Costs were measured based on the perspective of 
a health-care provider. Resource utilization derived from retrospective chart reviews 
of 14 mRCC patients treated at the King Chulalongkorn Memorial Hospital, Bangkok, 
Thailand. Costs and survival beneﬁ ts were discounted annually at 3%. RESULTS: 
The major assumption of the study was that the projected PFS and overall survival 
were longer for sunitinib than the other comparative treatments based on results of 
published studies. Additional treatment after failure of one tyrosine kinase inhibitor 
(TKI) in the model was limited which ﬁ t well with the practical scenario in developing 
country. Cost-effectiveness analyses demonstrated that IFNa had the most favorable 
cost-effectiveness ratio at 1.3 million Baht/QALYs followed by sunitinib, sorafenib, 
and bevacizumab at 1.7, 1.9, 9.3 million Baht/QALYs respectively. However, sunitinib 
had a better incremental cost-effectiveness ratios (ICERs) over IFNa at 2.0 million 
Baht/PFY, 2.7 million Baht/LYG, and 3.6 million Baht/QALY gained. Sensitivity 
analysis showed that the most sensitive parameters for sunitinib were the overall 
survival efﬁ cacy and costs. CONCLUSIONS: Our study reveals that sunitinib has the 
good cost-effectiveness proﬁ les as one of the ﬁ rst line treatment of mRCC. With 
current study model, it may be applicable to the situation in developing country with 
limit availability of TKIs in the treatment of mRCC. However, sunitinib’s ICER 
comparing to IFNa is still beyond the ICER threshold for a developing country. This 
cost-effectiveness evidence should be taken into account in conjunction with other 
clinical, societal and ethical considerations in the treatment of mRCC. 
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OBJECTIVES: Colorectal cancer (CRC) is one of the most common forms of cancer 
in western countries and represents the second leading cause of cancer mortality in 
Europe (AIRTUM, 2009). Early detection and removal of cancerous lesions can reduce 
the incidence of CRC, its mortality and improve patients’ quality of life (Taupin et al. 
2006). The main literature on this topic refers to USA and few studies have been 
conducted in Italy to date (Zappa et al. 1997; Tappenden et al. 2007). Aim of the 
paper is to shed some light on the effectiveness and costs of screening programs in the 
Italian health-care system, presenting the results of a cost-effectiveness analysis of a 
CRC screening program in Italy. METHODS: We use as case-study a Regional CRC 
screening program to determine the full costs and the effectiveness of the adopted 
techniques, FOBT combined with colonoscopy. The costs involved in each phase of 
the program are evaluated using a micro-costing analysis. Effectiveness is valued in 
terms of early detected lesions and years of life gained. Cost and effectiveness data 
are used to estimate the costs for year of life gained, using a MISCAN-COLON 
Model© to simulate and compare two alternative scenarios, with or without the 
screening program. RESULTS: The preliminary results show that the screening will 
prevent almost 2.0 deaths (11.2%) per 1000 screened individuals, corresponding to 
19.4 years of life gained in 30 years with an incremental cost effectiveness ratio of 
f2400 for life-year gained. CONCLUSIONS: The results outpace those of previous 
studies (Sonnenberg, 2000), signalling an increasing effectiveness of CRC screening 
program. Besides, the paper highlights the importance of implementing a screening 
not only for the effects that prevention can have in clinical terms, but also for the 
economic impact of such a policy in relation to the long-term sustainability of health-
care systems. 
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OBJECTIVES: This study aims to evaluate the cost-effectiveness of two aromatase 
inhibitors for adjuvant treatment of postmenopausal hormone receptor positive early 
breast cancer, and to address the most reasonable treatment option when population 
is stratiﬁ ed by nodal status. METHODS: A Markov model was developed deﬁ ning 
six Markov states based on breast cancer progression. Annual probabilities of recur-
rence by adjuvant treatment, anastrozole, letrozole, and tamoxifen were estimated 
from published studies in overall population, node negative, and node positive group. 
Costs of deﬁ ned breast cancer events were measured by micro-costing methods based 
on 2009 National Health Insurance Fee Schedule and the third Clinical Guideline of 
Breast Cancer Treatment. Anastrozole and letrozole were compared with tamoxifen, 
respectively, using the same Markov model. Incremental cost-effectiveness ratios 
(ICERs) in overall population and each subgroup were estimated. RESULTS: When 
